Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors.

Farrell PJ, Zopf CJ, Huang HJ, Balakrishna D, Holub C, Bilakovics J, Fanjul A, Matuszkiewicz J, Plonowski A, Rolzin P, Banerjee U, Ermolieff J, Cheruvallath ZS, McBride C, Bartkowski D, Mazur C, Pachori A, Larson CJ.

J Pharmacol Exp Ther. 2019 Nov;371(2):299-308. doi: 10.1124/jpet.119.259028. Epub 2019 Sep 19.

PMID:
31537613
2.

MetAP2 inhibition increases energy expenditure through direct action on brown adipocytes.

Huang HJ, Holub C, Rolzin P, Bilakovics J, Fanjul A, Satomi Y, Plonowski A, Larson CJ, Farrell PJ.

J Biol Chem. 2019 Jun 14;294(24):9567-9575. doi: 10.1074/jbc.RA118.007302. Epub 2019 May 2.

PMID:
31048375
3.

Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody.

Huang J, Ishino T, Chen G, Rolzin P, Osothprarop TF, Retting K, Li L, Jin P, Matin MJ, Huyghe B, Talukdar S, Bradshaw CW, Palanki M, Violand BN, Woodnutt G, Lappe RW, Ogilvie K, Levin N.

J Pharmacol Exp Ther. 2013 Aug;346(2):270-80. doi: 10.1124/jpet.113.204420. Epub 2013 May 29.

PMID:
23720456
4.

A Potent and Selective AMPK Activator That Inhibits de Novo Lipogenesis.

Gómez-Galeno JE, Dang Q, Nguyen TH, Boyer SH, Grote MP, Sun Z, Chen M, Craigo WA, van Poelje PD, MacKenna DA, Cable EE, Rolzin PA, Finn PD, Chi B, Linemeyer DL, Hecker SJ, Erion MD.

ACS Med Chem Lett. 2010 Aug 30;1(9):478-82. doi: 10.1021/ml100143q. eCollection 2010 Dec 9.

Supplemental Content

Loading ...
Support Center